<DOC>
	<DOCNO>NCT00287105</DOCNO>
	<brief_summary>The purpose study determine whether Imatinib safe effective association intensive treatment Ph+ALL child .</brief_summary>
	<brief_title>Safety Efficacy Imatinib Added Chemotherapy Treatment Ph+ Acute Lymphoblastic Leukemia Children</brief_title>
	<detailed_description>Recent advance treatment increase cure childhood ALL 75 % good . However , attempt improve result resistant subtypes ALL , Ph+ ALL , largely unsuccessful . Imatinib , inhibitor protein-tyrosine kinase , currently test several phase I , II III trial cover Chronic Myeloid Leukemia patient population patient overtly relapse refractory Ph+ALL . Pediatric patient Ph+ALL receive Imatinib , add intensive , post-induction BFM-type chemotherapy . The endpoint evaluation long-term clinical outcome , particular Disease Free Survival ( DFS ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Children adolescent age 1 17 year diagnostic Documented Ph+ ALL Eligibility current local prospective therapeutic study childhood ALL Informed consent give parent legal guardian Abnormal hepatic function Abnormal renal function Active systemic bacterial , fungal viral infection</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Children</keyword>
	<keyword>Philadelphia chromosome</keyword>
	<keyword>Protein-tyrosine kinase inhibitor</keyword>
</DOC>